Piperidine- and Piperazineacetamides as 17beta Hydroxysteroid Dehydrogenase Type 3 Inhibitors for the Treatment of Androgen Dependent Diseases

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14310%2F03%3A00036033" target="_blank" >RIV/00216224:14310/03:00036033 - isvavai.cz</a>

Result on the web

—

DOI - Digital Object Identifier

—

Result language

angličtina

Original language name

Piperidine- and Piperazineacetamides as 17beta Hydroxysteroid Dehydrogenase Type 3 Inhibitors for the Treatment of Androgen Dependent Diseases

Original language description

Compds. of formula I [R1 = aryl, heteroaryl, arylalkyl, heteroarylalkyl, diphenylalkyl, etc.; R2, R3 = H, OH, alkoxy, alkyl, cycloalkyl, etc.; R4, R5, R7, R8 = H, substituted OH, substituted amino, alkyl, aryl, cycloalkyl, etc.; R6 = acyl, substituted sulfonyl; R9, R10 = H, F, CF3, alkyl, cycloalkyl, arylalkyl, etc.; X, Z = C, N] are prepd. which are useful as inhibitors of Type 3 17.beta.-Hydroxysteroid Dehydrogenase. Also disclosed are pharmaceutical compns. contg. said compds. and their use for the treatment or prevention of androgen dependent diseases. Thus, II was prepd. in several steps. The prepd. compds. had type 3 17.beta.-hydroxysteroid dehydrogenase binding activity of 0.010 to 100 nM.

Czech name

—

Czech description

—

Type

P - Patent

CEP classification

FD - Oncology and haematology

OECD FORD branch

—

Project

—

Continuities

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Publication year

2003

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Patent/design ID

WO 2003/33487 A1

Publisher

—

Publisher name

—

Place of publication

—

Publication country

—

Date of acceptance

Apr 24, 2003

Owner name

Schering-Plough

Method of use

A - Výsledek využívá pouze poskytovatel

Usage type

A - K využití výsledku jiným subjektem je vždy nutné nabytí licence